Aquestive has resubmitted its needle-free epinephrine film after an FDA rejection over usability, not efficacy. This FAQ covers what changed.
News|Articles|February 3, 2026
7 Allergy Headlines You Missed in January 2026
Author(s)Chelsie Derman
Fact checked by: Alex Hillenbrand
FDA clears pediatric HAE oral therapy as intranasal epinephrine and heat-treated peanut/egg OIT studies point to safer allergy care.
Advertisement
Advertisement
January brought several noteworthy updates in
Related to this article
The resubmission follows an FDA Complete Response Letter and cites human factors data showing pouch-opening time fell from 17 to 3 seconds.
What lonvo-z is, how it works, and what a Priority Review designation means for the HAE gene-editing therapy.
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
In this Q&A, Alysse Wurcel, MD, translates qualitative barriers into 8 concrete tactics healthcare practices can use to expand penicillin allergy delabeling.
Jim Blando, PhD, of Old Dominion University, explains why allergic patients' lung function dropped most 1 year after wildfire smoke exposure.
A multi-site qualitative study identifies communication, language, and access barriers standing in the way of removing incorrect penicillin allergy labels.
New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.
Advertisement
Advertisement